Health Professional Radio - Podcast

Dr. Avi Fischer, M.D., Divisional Vice President, MedicalAffairs, and Chief Medical Officer for Cardiac RhythmManagement (CRM) at Abbott discusses the recent FDA approval of the next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The new devices offer built-in smartphone connectivity via Bluetooth for increased patient-physician engagement and streamlined communications. The Gallant high voltage platforms connect to Abbott’s secure myMerlinPulse™ mobile app to allow for continuous remote monitoring and seamlessly integrates into people’s day-to-day lives.